138 related articles for article (PubMed ID: 38247975)
1. Effect of Different Approaches to Antimicrobial Therapy with Cefmetazole and Meropenem on the Time to Defervescence in Non-Severe Extended-Spectrum β-Lactamase-Producing
Hoshi T; Fujii S; Watanabe K; Fukumura Y; Miyazaki K; Takahashi M; Taniguchi S; Kimura S; Saito A; Wada N; Saijo M; Yamada K; Iwayama K; Itaya M; Sato H
Infect Dis Rep; 2023 Dec; 16(1):26-34. PubMed ID: 38247975
[TBL] [Abstract][Full Text] [Related]
2. Change in the Antimicrobial Resistance Profile of Extended-Spectrum β-Lactamase-Producing
Miyazaki M; Yamada Y; Matsuo K; Komiya Y; Uchiyama M; Nagata N; Takata T; Jimi S; Imakyure O
J Clin Med Res; 2019 Sep; 11(9):635-641. PubMed ID: 31523337
[TBL] [Abstract][Full Text] [Related]
3. Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments.
Takemura W; Tashiro S; Hayashi M; Igarashi Y; Liu X; Mizukami Y; Kojima N; Morita T; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K
Pharm Res; 2021 Nov; 38(11):1839-1846. PubMed ID: 34853981
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Cefmetazole for Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Enterobacterales vs Carbapenems: A Retrospective Study.
Kashihara E; Sada RM; Tsugihashi Y; Obayashi H; Nakamura A; Abe N; Miyake H; Akebo H
Open Forum Infect Dis; 2023 Oct; 10(10):ofad502. PubMed ID: 37901123
[TBL] [Abstract][Full Text] [Related]
5. Successful de-escalation antibiotic therapy using cephamycins for sepsis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia: A sequential 25-case series.
Kuwana T; Yamaguchi J; Kinoshita K; Hori S; Ihara S; Taniguchi T
Open Med (Wars); 2020; 15(1):782-786. PubMed ID: 33336036
[TBL] [Abstract][Full Text] [Related]
6. In vitro Activity of Cefmetazole and Flomoxef among Extended-Spectrum Beta-Lactamase producing Enterobacterales.
Iio K; Hagiya H; Higashionna T; Otsuka F
New Microbiol; 2024 Jan; 46(4):348-353. PubMed ID: 38252045
[TBL] [Abstract][Full Text] [Related]
7. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia.
Matsumura Y; Yamamoto M; Nagao M; Komori T; Fujita N; Hayashi A; Shimizu T; Watanabe H; Doi S; Tanaka M; Takakura S; Ichiyama S
Antimicrob Agents Chemother; 2015 Sep; 59(9):5107-13. PubMed ID: 26100708
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics of Bacteremia Caused by Extended-spectrum Beta-lactamase-producing Escherichia coli at a Tertiary Hospital.
Namikawa H; Yamada K; Fujimoto H; Oinuma KI; Tochino Y; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
Intern Med; 2017; 56(14):1807-1815. PubMed ID: 28717075
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of cefmetazole versus carbapenems and piperacillin/tazobactam as initial therapy for bacteremic acute cholangitis: A retrospective study.
Aoto K; Inose R; Kosaka T; Shikata K; Muraki Y
J Infect Chemother; 2024 Mar; 30(3):213-218. PubMed ID: 37832824
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli].
Sugawara T; Murakami N; Uetake N; Hiraki K
Yakugaku Zasshi; 2015; 135(6):829-33. PubMed ID: 26028418
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
Yamamoto A; Yamasaki K
Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
14. Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli.
Hamada Y; Matsumura Y; Nagashima M; Akazawa T; Doi Y; Hayakawa K
J Infect Chemother; 2021 Nov; 27(11):1602-1606. PubMed ID: 34348852
[TBL] [Abstract][Full Text] [Related]
15. [Antimicrobial activity of several drugs against extended-spectrum beta-lactamase positive Enterobacteriaceae isolates in Gifu and Aichi prefecture].
Nakagawa S; Hisada H; Nomura N; Mitsuyama J; Matsubara S; Yamaoka K; Watanabe K; Asano Y; Suematsu H; Sawamura H; Hashido H; Yamagishi Y; Mikamo H; Matsukawa Y
Jpn J Antibiot; 2013 Oct; 66(5):251-64. PubMed ID: 24527516
[TBL] [Abstract][Full Text] [Related]
16. Infective Endocarditis Caused by Extended-Spectrum Beta-Lactamase-Producing
Kenzaka T; Shinkura Y; Kayama S; Yu L; Kawakami S; Sugai M; Kawasaki S
Infect Drug Resist; 2021; 14():3357-3362. PubMed ID: 34471362
[TBL] [Abstract][Full Text] [Related]
17. Cefmetazole Resistance Mechanism for
Ito R; Kawamura M; Sato T; Fujimura S
Infect Drug Resist; 2022; 15():5867-5878. PubMed ID: 36237294
[TBL] [Abstract][Full Text] [Related]
18. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Efficacy of Meropenem-Cefmetazole Combination Therapy against New Delhi Metallo-β-lactamase-producing Enterobacteriaceae.
Hagiya H; Sugawara Y; Tsutsumi Y; Akeda Y; Yamamoto N; Sakamoto N; Shanmugakani RK; Abe R; Takeuchi D; Nishi I; Ishii Y; Hamada S; Tomono K
Int J Antimicrob Agents; 2020 Mar; 55(3):105905. PubMed ID: 31991221
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
